456 related articles for article (PubMed ID: 19229762)
1. Recent experience with fungaemia: change in species distribution and azole resistance.
Chakrabarti A; Chatterjee SS; Rao KL; Zameer MM; Shivaprakash MR; Singhi S; Singh R; Varma SC
Scand J Infect Dis; 2009; 41(4):275-84. PubMed ID: 19229762
[TBL] [Abstract][Full Text] [Related]
2. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
Krcmery V; Barnes AJ
J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.
Pemán J; Cantón E; Quindós G; Eraso E; Alcoba J; Guinea J; Merino P; Ruiz-Pérez-de-Pipaon MT; Pérez-del-Molino L; Linares-Sicilia MJ; Marco F; García J; Roselló EM; Gómez-G-de-la-Pedrosa E; Borrell N; Porras A; Yagüe G;
J Antimicrob Chemother; 2012 May; 67(5):1181-7. PubMed ID: 22351683
[TBL] [Abstract][Full Text] [Related]
4. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
5. Candida glabrata fungaemia in intensive care units.
Ruan SY; Lee LN; Jerng JS; Yu CJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):136-40. PubMed ID: 18042196
[TBL] [Abstract][Full Text] [Related]
6. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.
Ruan SY; Huang YT; Chu CC; Yu CJ; Hsueh PR
Int J Antimicrob Agents; 2009 Sep; 34(3):236-9. PubMed ID: 19361960
[TBL] [Abstract][Full Text] [Related]
7. Candida glabrata fungemia: experience in a tertiary care center.
Malani A; Hmoud J; Chiu L; Carver PL; Bielaczyc A; Kauffman CA
Clin Infect Dis; 2005 Oct; 41(7):975-81. PubMed ID: 16142662
[TBL] [Abstract][Full Text] [Related]
8. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
[TBL] [Abstract][Full Text] [Related]
9. The increased role of non-albicans species in candidaemia: results from a 3-year surveillance study.
Tan TY; Tan AL; Tee NW; Ng LS; Chee CW
Mycoses; 2010 Nov; 53(6):515-21. PubMed ID: 19619263
[TBL] [Abstract][Full Text] [Related]
10. [Multicenter study of fungemia due to yeasts in Argentina].
Rodero L; Davel G; Soria M; Vivot W; Córdoba S; Canteros CE; Saporiti A;
Rev Argent Microbiol; 2005; 37(4):189-95. PubMed ID: 16502638
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005.
Borg-von Zepelin M; Kunz L; Rüchel R; Reichard U; Weig M; Gross U
J Antimicrob Chemother; 2007 Aug; 60(2):424-8. PubMed ID: 17562683
[TBL] [Abstract][Full Text] [Related]
12. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in São Paulo, Brazil, 1995-2003.
da Matta DA; de Almeida LP; Machado AM; Azevedo AC; Kusano EJ; Travassos NF; Salomão R; Colombo AL
Diagn Microbiol Infect Dis; 2007 Apr; 57(4):399-404. PubMed ID: 17240110
[TBL] [Abstract][Full Text] [Related]
13. Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: an analysis of microbiological data.
Samonis G; Kofteridis DP; Saloustros E; Giannopoulou KP; Ntziora F; Christidou A; Maraki S; Falagas ME
Scand J Infect Dis; 2008; 40(5):414-9. PubMed ID: 18418802
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of candidemia in a Turkish tertiary care hospital.
Bakir M; Cerikcioglu N; Barton R; Yagci A
APMIS; 2006 Sep; 114(9):601-10. PubMed ID: 16948812
[TBL] [Abstract][Full Text] [Related]
15. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital.
Muñoz P; Sánchez-Somolinos M; Alcalá L; Rodríguez-Créixems M; Peláez T; Bouza E
J Antimicrob Chemother; 2005 Feb; 55(2):188-93. PubMed ID: 15650001
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and treatment of hematogenous candidiasis: a Brazilian perspective.
Colombo AL
Braz J Infect Dis; 2000 Jun; 4(3):113-8. PubMed ID: 10934493
[TBL] [Abstract][Full Text] [Related]
18. Emergence of Candida tropicalis as the major cause of fungaemia in India.
Mathews MS; Samuel PR; Suresh M
Mycoses; 2001; 44(7-8):278-80. PubMed ID: 11714062
[TBL] [Abstract][Full Text] [Related]
19. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999.
Cheng MF; Yu KW; Tang RB; Fan YH; Yang YL; Hsieh KS; Ho M; Lo HJ
Diagn Microbiol Infect Dis; 2004 Jan; 48(1):33-7. PubMed ID: 14761719
[TBL] [Abstract][Full Text] [Related]
20. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit.
Bassetti M; Ansaldi F; Nicolini L; Malfatto E; Molinari MP; Mussap M; Rebesco B; Bobbio Pallavicini F; Icardi G; Viscoli C
J Antimicrob Chemother; 2009 Sep; 64(3):625-9. PubMed ID: 19622536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
